Committee

Concerned Shareholders of Rocky Mountain Comment on the Board’s Last-Minute Attempt to Circumvent the Shareholder Franchise

Monday, September 20, 2021 - 10:53pm

The group strenuously objects to the Boards unilateral decision approximately two weeks before the annual shareholder vote.

Key Points: 
  • The group strenuously objects to the Boards unilateral decision approximately two weeks before the annual shareholder vote.
  • The Concerned Shareholders of Rocky Mountain believe that, facing a potential loss of an incumbent majority of director seats, the Board chose desperation over proper governance.
  • We believe that despite the Boards excuse for its decision, shareholders know the likely real reason and motivation preventing the Concerned Shareholders of Rocky Mountain from winning Board seats.
  • Ultimately, this Board contraction tactic disenfranchises shareholders and is a poor substitute compared to the option of genuine, immediate change.

Katten Bankruptcy Team Wins Numerous Turnaround Awards From The M&A Advisor

Monday, September 20, 2021 - 9:45pm

Moreover, the Katten team has broad experience in handling Chapter 15 cases, acquisitions of distressed assets, and representing creditors' committees.

Key Points: 
  • Moreover, the Katten team has broad experience in handling Chapter 15 cases, acquisitions of distressed assets, and representing creditors' committees.
  • Katten represented the independent directors of J.C. Penney Corporation, Inc. in its Chapter 11 cases.
  • The Katten team was led by Steven J. Reisman and included Insolvency and Restructuring partner Geoffrey King and Litigation partner Robert T. Smith.
  • Katten represents public and private companies in numerous industries, as well as a number of government and nonprofit organizations and individuals.

Port Houston Commission Meetings Notice

Monday, September 20, 2021 - 6:08pm

The Port Commission of the Port of Houston Authority will conduct its Regular Monthly Meeting on September 28, 2021 at 9:15 a.m. as a hybrid meeting.

Key Points: 
  • The Port Commission of the Port of Houston Authority will conduct its Regular Monthly Meeting on September 28, 2021 at 9:15 a.m. as a hybrid meeting.
  • The Commissioners, executive leadership, and legal counsel will be present in the boardroom of the Port Authority Executive Office Building, located at 111 East Loop North, Houston, TX 77029.
  • The Pension and Benefits Committee will meet on Tuesday, September 21st at 10:00 a.m.
    Sign up for public comment is available up to an hour before the Port Commission Regular Monthly, Committee and Advisory Council meetings by contacting Erik Eriksson at eeriksson@porthouston.com or Liana Christian at lchristian@porthouston.com .
  • For more than 100 years, Port Houston has owned and operated the public wharves and terminals along the Houston Ship Channel the nations largest port for waterborne tonnage and an essential economic engine for the Houston region, the state of Texas, and the U.S. nation.

FORTUNE Launches Philanthropic Fund Alongside NFT Artist pplpleasr on the Ethereum Blockchain

Monday, September 20, 2021 - 5:00pm

NEW YORK, Sept. 20, 2021 /PRNewswire/ -- FORTUNE and digital artist pplpleasr have announced the FORTUNE Journalism PleasrFund , a decentralized donor-advised fund run entirely on the Ethereum blockchain, through Endaoment .

Key Points: 
  • NEW YORK, Sept. 20, 2021 /PRNewswire/ -- FORTUNE and digital artist pplpleasr have announced the FORTUNE Journalism PleasrFund , a decentralized donor-advised fund run entirely on the Ethereum blockchain, through Endaoment .
  • The FORTUNE Journalism PleasrFund donates 209 ETH to support independent journalism through the Endaoment platform.
  • This fund will serve the public interest, further accountability and transparency through journalism, and contribute to critical thinking and well-informed debate.
  • The FORTUNE Journalism PleasrFund requires that all recipient organizations adhere to Endaoment's funding policy and be U.S.-based 501(c)(3) organizations.

Alvotech Provides Update on FDA Action Regarding AVT02, Proposed High-Concentration Biosimilar to Humira® (adalimumab)

Monday, September 20, 2021 - 3:23pm

Alvotech, a multinational biopharmaceutical company focused on the development and manufacturing of high quality biosimilars for global markets, today announced that the FDA is deferring action on the application for AVT02, the companys proposed biosimilar to Humira, until facility assessments can be completed.

Key Points: 
  • Alvotech, a multinational biopharmaceutical company focused on the development and manufacturing of high quality biosimilars for global markets, today announced that the FDA is deferring action on the application for AVT02, the companys proposed biosimilar to Humira, until facility assessments can be completed.
  • Alvotech continues to work with the FDA to coordinate the required inspection(s) in a safe and adequate manner.
  • Our fully integrated approach, with high-quality in-house competencies throughout the value chain, enables the accelerated development of biosimilar products.
  • AVT02 is a monoclonal antibody and a proposed biosimilar to Humira (adalimumab).

Deciphera Announces Positive CHMP Opinion for QINLOCK® for the Treatment of Fourth-line Gastrointestinal Stromal Tumor

Friday, September 17, 2021 - 1:17pm

Deciphera Press Release: FDA Grants Full Approval of Deciphera Pharmaceuticals QINLOCK (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor [online] May 15, 2020.

Key Points: 
  • Deciphera Press Release: FDA Grants Full Approval of Deciphera Pharmaceuticals QINLOCK (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor [online] May 15, 2020.
  • Deciphera Press Release: Deciphera Announces Australian Therapeutic Goods Administrations Approval of QINLOCK (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor [online] July 14, 2020.
  • Deciphera Press Release: Deciphera Announces Health Canadas Authorization of QINLOCK (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor [online] June 22, 2020.
  • Zai Lab Press Release: QINLOCK (Ripretinib) Approved in Taiwan for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST) [online] September 1, 2021.

GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Friday, September 17, 2021 - 12:15pm

Dr Walid Abi-Saab, Chief MedicalOfficerat Galapagos, said: Ulcerative colitis can have significant and profound effects on the people who suffer with the condition.

Key Points: 
  • Dr Walid Abi-Saab, Chief MedicalOfficerat Galapagos, said: Ulcerative colitis can have significant and profound effects on the people who suffer with the condition.
  • Todays decision brings us one step closer to providing a new treatment option for people living with this chronic disease.
  • The CHMP positive opinion will now be reviewed by the European Commission and a decision is expected before year end 2021.
  • This positive opinion follows the previous approval of filgotinib for the treatment of patients with moderate to severe active rheumatoid arthritis.

Alvotech Welcomes Positive CHMP Opinion for AVT02, a Proposed Biosimilar to Humira®

Friday, September 17, 2021 - 12:48pm

Alvotech today welcomed the positive opinion of the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending the approval of Alvotechs high-concentration AVT02 (100 mg/mL), a proposed biosimilar to Humira (adalimumab).

Key Points: 
  • Alvotech today welcomed the positive opinion of the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending the approval of Alvotechs high-concentration AVT02 (100 mg/mL), a proposed biosimilar to Humira (adalimumab).
  • The CHMPs positive opinion will now be referred to the European Commission (EC) for the decision to grant a marketing authorization for AVT02.
  • Humira recorded global sales of about US$20 billion in 2020, making it the largest-selling biologic medicine in the world.
  • We are delighted by the CHMPs recommendation to approve our high-concentration biosimilar candidate for Humira, said Rbert Wessman, Founder and Chairman of Alvotech.

Navidea Biopharmaceuticals Announces Changes to Board of Directors Composition

Friday, September 17, 2021 - 12:30pm

Following the retirement of Dr. Rouan as Chair, the Board appointed Alexander L. Cappello and John K. Scott, Jr., who were both existing members of the Board, as Chair of the Board and Vice Chair of the Board, respectively.

Key Points: 
  • Following the retirement of Dr. Rouan as Chair, the Board appointed Alexander L. Cappello and John K. Scott, Jr., who were both existing members of the Board, as Chair of the Board and Vice Chair of the Board, respectively.
  • Jed Latkin, Navideas CEO said, We thank both Kathy and Claudine for their service on the Board and the valuable insights they have provided over the years.
  • Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics.
  • The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform.

NAVER Bolsters AI R&D Capability, Appoints Global leading AI Professionals in Search Quality and Natural Language Processing

Friday, September 17, 2021 - 1:30am

SEONGNAM, South Korea, Sept. 16, 2021 /PRNewswire/ -- NAVER Corporation today announced that the company is bolstering its global AI R&D belt with outstanding artificial intelligence experts in search quality evaluation and natural language processing. NAVER expects to accelerate cooperation within its AI community by expanding its talents with robust experience and knowledge in the field.   

Key Points: 
  • - NAVER to strengthen cooperation throughout the global AI R&D belt, and upgrade its AI search and recommendation services by bringing in global talents
    SEONGNAM, South Korea, Sept. 16, 2021 /PRNewswire/ --NAVER Corporation today announced that the company is bolstering its global AI R&D belt with outstanding artificial intelligence experts in search quality evaluation and natural language processing.
  • NAVER expects to accelerate cooperation within its AI community by expanding its talents with robust experience and knowledge in the field.
  • To that end, NAVER appointed Dr. Young-Bum Kim, an AI expert in conversational AI as head of Applied Science and Executive Director of U.S. R&D at NAVER Search CIC.
  • Dr. Kim and Professor Sakai will work together and create synergies for upgrading NAVER's search and AI service.